Natixis reduced its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 89.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 3,500 shares of the biotechnology company’s stock after selling 28,209 shares during the period. Natixis’ holdings in Mirati Therapeutics were worth $126,000 at the end […]

Natixis cut its holdings in shares of ProShares Ultra QQQ (NYSEARCA:QLD – Free Report) by 58.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,399 shares of the company’s stock after selling 1,929 shares during the quarter. Natixis’ holdings in ProShares Ultra […]